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still excluded from having TAVR. FDA approval of TAVR resulted in overall in-
crease of both TAVR and SAVR, while the number of patients treated with BAV of
medical therapy continues to decline.
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Background: Although Transcatheter Aortic Valve Implantation (TAVI) has afﬁrmed
as a promising technique guaranteeing similar results to surgical aortic valve replace-
ment (SAVR), long-term data on valve function and clinical outcomes are limited. We
sought to assess 4-year clinical and echocardiographic outcomes in patients undergoing
Transcatheter Aortic Valve Implantation (TAVI) with CoreValve prosthesis.
Methods: Between June 2007 and February 2014, 450 consecutive patients with
symptomatic severe aortic stenosis underwent TAVI using both CoreValve, Edwards-
SAPIEN, and Lotus valves. For the purposes of this study we included only those
patients undergoing successful TAVI with CoreValve prosthesis who had a minimum
follow-up of 4 years (n¼125). All outcomes were deﬁned according to the Valve
Academic Research Consortium (VARC 2).
Results: Survival rates at 1, 2, 3 and 4 years were 83.2, 76.8, 73.6 and 66.3%, respec-
tively. Survival from cardiovascular mortality rates at 1, 2, 3 and 4 years were 88.0,
84.0, 83.2 and 80.8%, respectively. No deaths were directly related to valvular
dysfunction. Freedom from reoperation was 98.5%. We reported satisfactory long-term
valve performance in terms of mean pressure gradients and aortic valve area (AVA).
Echocardiographic follow-up revealed a mean pressure gradients decreasing from
5717.4 mmHg (pre-TAVI) to 10.44.5 mmHg (post-TAVI) (P>0.001) with a small
increase at 1 year (12.486.8 mmHg), which remained steady at 4 years (11.97.1
mmHg). In the majority of cases mild paravalvular regurgitation (PVR) were either
unchanged or slightly improved overtime. Progression frommild acute PVR tomoderate
PVR at 4-year follow-up was reported in three patients. Prosthetic valve failure was
reported in 4 patients (3.2%). Valve thrombosis or late valve embolization were not
reported.
Conclusions: Our study demonstrated that favorable outcomes after successful TAVI
are associated with sustained clinical and functional cardiovascular beneﬁts up to
4-year follow-up. Signs of moderate prosthetic valve failure are present only in a small
percentage of patients.TCT-730
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Background: There is limited information on 5-year outcome of patients undergoing
transcatheter aortic valve implantation. In particular, long-term results of a non-
metallic inﬂatable valve design have never been reported. The aim of the present study
was to evaluate the 5-year clinical and echocardiographic outcome of the ﬁrst gen-
eration retrievable and repositionable 22F Direct Flow Medical Valve percutaneous
aortic valve.
Methods: From 2007 to 2008, 31 symptomatic high-risk for surgery patients (mean
age 824y) with severe aortic stenosis and a mean logistic EuroSCORE of 297%
were the enrolled in this study. Clinical, echocardiographic and hemodynamic follow-
up were obtained during 5 years.
Results: Survival rates were 81%, 69%, 60%, 54%, and 54% at 1,2,3,4, 5 years,
respectively. At 5 years, all surviving patients were NYHA-class I. Echocardiography
revealed a signiﬁcant decrease in the mean gradient from baseline (49.113.8 mmHg)
to 30 days (19.16.8 mmHg) and remained stable over 5 years (15.36.0 mmHg) (p
¼ NS). At 5-year follow-up, aortic regurgitation assessed by TTE was either trace or
none in all patients.
Conclusions: In this preliminary series of , the ﬁrst generation of the nonmetallic,
repositionable and retrievable 22F Direct Flow Medical valve resulted in the acute
hemodyananmic performance was and sustained stable hemodynamic performance
over 5 years including with no or trace aortic regurgitation in the majority of all
patients.
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Background: Elderly patients with severe aortic stenosis and numerous cardiac and
non-cardiac comorbidities are currently considered for transcatheter aortic valve im-
plantation (TAVI). TAVI is effective in alleviating valve-related symptoms and
restoring quality of life. However, many patients remain frail and in a vulnerable
clinical condition after successful TAVI. The aim of this study was to assess rates and
reasons for rehospitalization within one year after TAVI.
Methods: Between August 2007 and September 2012, 549 consecutive patients with
degenerative aortic stenosis underwent TAVI using different access routes and devices
and were included into a prospective registry. Active follow-up was scheduled at 30
days, 6 months and 1 year. All hospital readmissions were ascertained and major
adverse events were adjudicated according to the VARC2 standardized endpoint
deﬁnitions.
Results: Of 549 patients undergoing TAVI, 529(96.4%) were alive at the end of the
index hospitalization and discharged. Of these, 138(26.1%) patients were readmitted
within 1 year of discharge and included in the present analysis. Patients with at least
one readmission had presented with higher logistic EuroScore (25.116 vs.
22.113mmHg,p¼0.01), higher systolic pulmonary artery pressure (55.519 vs.
50.216mmHg,p¼0.02), lower left ventricular ejection fraction (49.016 vs.
53.314mmHg, p¼0.009) and more frequently had previous myocardial infarction
(21.7% vs. 13%,p¼0.02). Overall, 176 readmissions occurred during the observa-
tional period with a cumulative mean hospital duration of 15.616 days. Among
readmitted patients, 73 patients(41.5%) were re-evaluated for cardiovascular causes
(heart failure 17%, peripheral vascular disease 15%, 2% for valvular heart disease), 22
(13%) for gastrointestinal, 12 (7%) for respiratory and 8 patients (5%) for chronic
kidney disease. Twenty-two patients (13%) received non-cardiac surgery and 8 pa-
tients (5%) were found to have a malignant tumor.
Conclusions:Within the ﬁrst year after TAVI, one out of four patients is readmitted to
the hospital. Cardiac causes and vascular disease are among the most frequent reasons
for rehospitalization, while readmission for valve related issues is rare.
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Background: An impaired left ventricular ejection fraction (LVEF) severely affects
prognosis and peri-operative risk in patients undergoing surgical aortic valve
replacement. Also in patients undergoing TAVI, an impaired LVEF seems to affect
prognosis, although contradictory ﬁndings exist. We analyzed the effects of antember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
